Ferring B.V. v. Watson Laboratories Inc., No. 14-1416 (Fed. Cir. Aug. 22, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Watson Laboratories, Inc. – Florida (“Watson”) a p- peals from the decisions of the United States District Court for the District of Nevada (i) holding that the subject matter of the asserted claims of Ferring B.V.’s (“Ferring”) U.S. Patents 7,947,739 (the “’739 patent”), 8,022,106 (the “’106 patent”), and 8,273,795 (the “’795 patent”) would not have been obviou s under 35 U.S.C. § 103, (ii) finding that Watson’s generic tranexamic acid product infringed those claims under 35 U.S.C. § 271, consequently (iii) ordering the U.S.